geranylgeraniol has been researched along with pitavastatin in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bernini, F; Favari, E; Rothblat, GH; Sposito, AC; Zanotti, I | 1 |
| Abdullah, MI; de Wolf, E; Drijfhout, FP; Hart, SR; Hoskins, C; Jones, SM; Menezes, K; Moss, DM; Richardson, A; Stronach, EA | 1 |
| Abdullah, MI; Abed, MN; Richardson, A | 1 |
3 other study(ies) available for geranylgeraniol and pitavastatin
| Article | Year |
|---|---|
Pitavastatin increases ABCA1-mediated lipid efflux from Fu5AH rat hepatoma cells.
Topics: Animals; ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; Biological Transport; Carcinoma, Hepatocellular; Cell Line, Tumor; Cholesterol; Diterpenes; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Lipid Metabolism; Liver Neoplasms; Mevalonic Acid; Quinolines; Rats | 2004 |
Dietary geranylgeraniol can limit the activity of pitavastatin as a potential treatment for drug-resistant ovarian cancer.
Topics: Animals; Cell Line; Cell Line, Tumor; Cells, Cultured; Diet; Diterpenes; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mice, Nude; Mice, SCID; Ovarian Neoplasms; Quinolines; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2017 |
Inhibition of the mevalonate pathway augments the activity of pitavastatin against ovarian cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Diterpenes; Female; Geranyltranstransferase; GTP Phosphohydrolases; Humans; Imidazoles; Leucine; Mevalonic Acid; Naphthalenes; Ovarian Neoplasms; Quinolines; Zoledronic Acid | 2017 |